Conexeu Sciences Inc. (CNXU) - 10-Q Summary
Business Context and Reporting Period
Company: Conexeu Sciences Inc.
Reporting Period: Quarter and nine months ended July 31, 2026.
Business Overview: An early-stage regenerative medicine company developing biomaterial-based technologies for tissue restoration in wound care and aesthetics. The Company has no commercial sales to date.
Key Milestone: Commenced trading on the Nasdaq Capital Market under symbol "CNXU" via a direct listing on May 21, 2026.
Key Financial Metrics
| Metric | Three Months Ended July 31, 2026 | Nine Months Ended July 31, 2026 | Balance Sheet (July 31, 2026) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(7,725,651) | $(11,748,757) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.29) | $(0.52) | N/A |
| Cash & Cash Equivalents | N/A | N/A | $1,971,408 |
| Restricted Cash | N/A | N/A | $238,208 |
| Total Assets | N/A | N/A | $7,156,074 |
| Total Liabilities | N/A | N/A | $1,305,684 |
| Accumulated Deficit | N/A | N/A | $(16,270,277) |
| Net Cash Used in Operating Activities | N/A | $(10,099,279) | N/A |
| Net Cash Provided by Financing Activities | N/A | $7,548,009 | N/A |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased significantly to $7.69 million for the quarter (from $1.30 million in the prior year quarter) and $11.79 million for the nine-month period (from $2.09 million).
- Consulting: Increased by $3.32 million (quarter) and $4.78 million (nine months), driven largely by non-cash stock-based compensation issued to marketing and advisory vendors valued at Nasdaq trading prices.
- Business Development: Increased by $1.18 million (quarter) and $1.26 million (nine months), reflecting expanded marketing, investor relations, and travel costs associated with the Nasdaq listing.
- Management & Personnel: Increased by $1.06 million (quarter) due to executive team expansion and vesting of milestone warrants.
- Regulatory Fees: Increased by $206,371 (quarter) related to 510(k) submission preparations.
- Prepaid Expenses: Increased from $549,930 to $4,544,274, primarily due to $3.7 million in prepaid marketing and business development contracts.
- Financing: Net cash provided by financing activities rose to $7.55 million (nine months), driven by the collection of a $2.0 million private placement receivable and proceeds from a Warrant Exercise Incentive Program.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The Company has incurred recurring losses and an accumulated deficit of $16.3 million. Management states that existing cash resources are not sufficient to fund operations for the next twelve months, raising substantial doubt about the ability to continue as a going concern. Additional financing is required.
- Cash Burn: Average monthly cash burn was approximately $0.87 million for the quarter ended July 31, 2026, excluding one-time prepaid expenses. Including prepayments, the burn rate was higher ($2.3 million/month).
- Outlook: The Company anticipates submitting a 510(k) application to the FDA in the first quarter of calendar 2027. No revenue is expected in the near term.
- Unusual Items:
- Write-off of $73,169 in deferred offering costs due to the shift from an IPO to a direct listing.
- Significant non-cash stock-based compensation ($4.6 million for the nine months) related to shares and options issued for services.
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of July 31, 2026, due to a material weakness in the accounting for and disclosure of certain prepaid expenses. Remediation is underway.
- Subsequent Events: On September 4, 2026, the Company raised $1.75 million through warrant exercises.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for securing additional debt or equity financing given the stated inability to fund operations for 12 months.
- Prepaid Expense Recognition: Monitor the amortization schedule of the $3.7 million in prepaid marketing expenses to understand future cash burn impacts.
- Internal Control Remediation: Track progress on fixing the material weakness regarding prepaid expense accounting to ensure future financial reporting reliability.
- Regulatory Milestones: Confirm the timeline for the planned 510(k) FDA submission (anticipated Q1 2027) and associated costs.
- Dilution Risk: Review the impact of outstanding warrants (approx. 7.98 million) and options (735,000) on future share count and ownership dilution.